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Abstract
Introduction: The long-term treatment of rheumatoid arthritis (RA) most often involves a sequence of different
therapies. The response to therapy, disease progression and detailed knowledge of the role of different therapies
along treatment pathways are key aspects to help physicians identify the best treatment strategy. Thus,
understanding the effectiveness of different therapeutic sequences is of particular importance in the evaluation of
long-term RA treatment strategies. The objective of this study was to systematically review and quantitatively
evaluate the relationship between the clinical response to biologic treatments and the number of previous
treatments with tumor necrosis factor a (TNF-a) inhibitors.
Methods: A systematic search was undertaken to identify published, peer-reviewed articles that reported clinical
outcomes of biologic treatment among RA patients with an inadequate response to TNF-a inhibitors. Data were
systematically abstracted. Efficacy rates were estimated for groups of patients who differed in the number of prior
TNF-a inhibitors used. End points included American College of Rheumatology (ACR)-, European League Against
Rheumatism (EULAR)- and Disease Activity Score 28 (DAS28)-based response criteria.
Results: The literature search identified 41 publications, of which 28 reported biologic treatment outcomes for RA
patients with prior exposure to TNF-a inhibitors. Seven publications reported outcomes obtained in randomized
clinical trials, while the remaining consisted of observational studies. The likelihood of responding to a subsequent
biologic treatment decreased as the number of previous treatments with TNF-a inhibitors increased for six of the
seven response criteria examined.
Conclusions: For patients with prior exposure to TNF-a inhibitors, the likelihood of response to subsequent
treatment with biologic agents declines with the increasing number of previous treatments with TNF-a inhibitors.
Introduction
The chronic nature of rheumatoid arthritis (RA) and its
progression over time in spite of a variety of treatment
options implies that long-term treatment will most often
involve a sequence of therapies. The optimal therapeutic
sequence strategy will be determined largely by the
patient’s response to therapy and by disease progression,
as well as detailed knowledge of the role of different
therapies along treatment pat h w a y s .T h u s ,u n d e r s t a n d -
ing the effectiveness of different therapeutic sequences
is of particular importance in the evaluation of long-
term RA treatment strategies.
There are three main drug classes commonly used in
the treatment of RA: nonsteroidal anti-inflammatory
drugs (NSAIDs), corticosteroids and disease-modifying
antirheumatic drugs (DMARDs). Several studies [1-3]
have provided evidence that early treatment with
DMARDs results in superior clinical and radiological
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for the treatment of RA: synthetic DMARDs and biolo-
gic DMARDs. Oral administration, lower cost and
greater prescriber familiarity support the use of syn-
thetic DMARDs as a first-line strategy. Biologic
DMARDs, most often in combination with synthetic
DMARDs, are generally reserved for the treatment of
patients with moderate to severe RA who have had an
inadequate response or have developed toxicities to syn-
thetic DMARDs [4].
A review of 16 clinical practice guidelines and 20 con-
sensus statements on RA treatment revealed that while
tumor necrosis factor (TNF)-a inhibitors were consis-
tently recommended for patients with active RA and a
history of inadequate response to synthetic DMARDs
[5], the management of patients who stopped an initial
TNF-a treatment because of lack of initial response,
loss of initial response or side effects continues to be
the subject of much debate, and guidelines for patient
management are nearly absent. Despite the lack of
guidelines, it is estimated that upon encountering an
inadequate response or side effects with a TNF-a inhibi-
tor, over 90% of rheumatologists in the United States
switch patients to a different TNF-a inhibitor [6].
Estimates of efficacy rates of TNF-a inhibitors may
depend on a number of factors, including patient char-
acteristics, such as disease duration, prognostic factors,
number of previously failed DMARDs and disease activ-
ity, as well as the dose of TNF-a inhibitor and the
designs of the studies from which they were obtained.
Despite some variation attributable to these factors, esti-
mates derived from randomized, controlled trials (RCTs)
suggest that between 40% and 50% [7] of RA patients
treated for at least 6 months with one of the three first-
generation TNF-a inhibitors (etanercept, adalimumab
and infliximab) failed to achieve the American College
of Rheumatology 50% (ACR50) improvement criteria
[8], while the results from a large, registry-based study
[9] indicated that over 70% of these patients fail to
achieve Disease Activity Score 28 joint count (DAS28)-
defined “remission” (DAS28 <2.6).
Although the efficacy of TNF-a inhibitors in patients
who are naïve to biologic treatment has been evaluated
in multiple studies [10-12], evaluating the efficacy of
these drugs in patients who have already experienced an
inadequate response to a TNF-a inhibitor poses greater
methodological challenges. One key aspect of evaluating
the efficacy of sequential TNF-a therapy is to determine
whether the probability of responding to a TNF-a inhi-
bitor depends on the results of prior treatment with
these drugs. Early evidence from small observational
studies suggested that a significant proportion of
patients who had an inadequate response to an initial
TNF-a inhibitor benefited from subsequent treatment
with an alternative TNF-a inhibitor [13-15]. Recent data
derived from registries, however, have suggested that the
response rates of patients switching to a second or third
TNF-a inhibitor are often lower than the response rates
of patients to the first TNF-a inhibitor [16,17]. More-
over, the broader question whether it is more effective
to switch to another mechanism of action or to use a
second TNF-a inhibitor after the patient has had an
inadequate response to a first one has not been formally
addressed.
In the present study, several biologic treatment
options currently available to RA patients with an inade-
quate response to an initial TNF-a inhibitor were
evaluated using evidence gathered from published
reports. We undertook a systematic review of published,
peer-reviewed studies that reported clinical outcomes of
biologic treatment among this group of patients. Our
study expands on previously published reviews in two
ways: first, information on efficacy rates of newer biolo-
gics with different mechanisms of action among patients
with an inadequate response to TNF-a inhibitors was
also included and results were examined separately for
TNF-a inhibitors and other biologic DMARDs; second,
a quantitatively based evaluation of the relationship
between response to biologic treatment and the number
of failed TNF-a inhibitors was undertaken by summariz-
ing the results of published studies. Within the limita-
tions of the existing data, potential effect-modifying
factors, such as study design and treatment duration,
were also examined. A secondary objective of this study
was to determine whether clinical response to a subse-
quent TNF-a differed by reason for discontinuation.
Materials and methods
Search strategy
A search was carried out in the PubMed database using
each of the following search terms as keywords or text
words: “golimumab,”“ adalimumab,”“ infliximab,”
“etanercept,”“ abatacept,”“ rituximab,”“ anakinra,”“ tocili-
zumab,”“ certolizumab pegol,”“ anti-TNF,”“ TNF-antago-
nist,”“ TNF-inhibitor,”“ biologic*” in combination with
“switch*” or “sequential therapy” or “therapy inter-
change,” and “rheumatoid arthritis.” Brand names of
biologics were also used for each of the drugs cited
above. The search was restricted to the English language
and had an end date of 31 December 2009. The refer-
ence lists of selected review publications were further
examined to identify any studies that were not captured
by our search.
Articles were included in the analyses if the publica-
tions reported any quantitative clinical and/or health-
related quality of life outcomes for RA patients
previously failing one or more TNF-a inhibitors. Studies
with fewer than 20 participants were excluded.
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The characteristics of each study were recorded, includ-
ing the study design and major findings. Disease dura-
tion, age, sex distribution, duration of treatment,
duration of washout period (if reported), concomitant
use of methotrexate (percentage of patients within the
group), dose of biologic drug and all clinical and qual-
ity-of-life measures were recorded for each group of
patients on the basis of the total number of biologics
that had been tried at the time the outcome was mea-
sured. Studies differed with respect to the way in which
washout periods were reported. For this study, washout
periods were noted in the following manner: (1) if the
mean or median was reported (the median was pre-
ferred if both were reported) for the time elapsed
between the last dose of prior treatment until the first
dose of subsequent treatment, this value was recorded;
and (2) if no summary statistic for the washout period
was reported, the minimum washout period required
per study protocol was recorded. For RCTs in which dif-
ferent doses of biologic DMARDs were administered,
efficacy estimates based on all study arms were included.
The sensitivity of the results to this parameter was
assessed in the analyses.
Some studies reported outcomes of multiple switches
for the same group of patients, so the same group of
patients might have contributed to more than one com-
bination of outcome measures and number of biologics
tried. A few studies did not report results disaggregated
by the actual number of prior TNF-a inhibitors tried
and reported only the results of the biologic under
study for subjects with an inadequate response to at
least one TNF-a inhibitor (in these cases, the number of
biologics under study was recorded as 2+).
Several studies did not allow for within-study evalua-
tion of differences in clinical or health-related quality-
of-life outcomes across groups differing in the number
of previous TNF-a inhibitors used. For these studies,
the results of various outcome measures were reported
for a single comparison group.
Efficacy estimates
All estimates were evaluated for each combination of
measure and biologic number (that is, first, second, and
so on), as well as for relevant subgroups. All estimates
were evaluated as weighted averages using sample size
as the weight in the following formula:
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where Ratej represents the average response rate for
measure j, i indexes the group, ni is the sample size for
the ith group and N is the combined sample size of all
groups.
The main focus was on estimating the efficacy rate on
the basis of each of the main response criteria reported
in the studies identified by our review across the num-
ber of previously failed biologics. Nevertheless, some of
the publications included in the current study also
reported efficacy rates associated with a first trial of
TNF-a treatment. Weighted estimates were also evalu-
ated for this group of patients and served as a further
check of how the values obtained in the current study
compared to published rates. Estimates were also evalu-
ated within the following subgroups: type of study
(observational study versus RCT), duration of follow-up
(<6 months versus 6 months or longer), type of biologic
(TNF-a inhibitor versus other) and reason for disconti-
nuation (lack of response, loss of response or
intolerance).
Results
Characteristics of biologic treatments for RA
Table 1 presents a brief overview of current biologic
DMARDs, including their brand names, dates of
approval by the Food and Drug Administration for the
treatment of RA, mode of action and schedule of
administration.
Study characteristics
On the basis of an abstract review, 41 publications were
identified as potentially reporting clinical outcomes of
patients who had switched to a second or subsequent
biologic DMARD. Upon full review of the 41 publica-
tions, 28 were included in the study. The remaining 13
publications [16,18-29] were excluded for one or more
of the following reasons: (1) the information reported
was not relevant to the objective of our analysis, (2)
quantitative results could not be extracted from the
publication, and/or (3) the study sample did not include
patients with an inadequate response to one or more
TNF-a inhibitors. Our search did not uncover any
information that pertained to the effect of certolizumab
pegol or anakinra for the treatment of patients with an
inadequate response to TNF-a inhibitors. Two [30,31]
of the 28 publications included reports that contained
analyses of patients with conditions other than RA. The
percentage of RA patients was 80% and 95% across
these two studies. Both studies were small, with a com-
b i n e ds a m p l es i z eo f9 3p a t i e n t s .O ft h e2 6r e m a i n i n g
publications, five were randomized trials (one was not
placebo-controlled). One publication [32] reported
results associated with different doses of tocilizumab (4
and 8 mg).
Key characteristics of the 28 [14,15,17,29-53] selected
publications, including a brief description of their key
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tional file 1). The studies used in specific subgroup ana-
lyses are also identified.
Outcome measures
The types of outcome measures reported across the 28
publications differed considerably. The most commonly
reported efficacy measures were ACR-, European League
Against Rheumatism (EULAR)- and DAS28-based
response criteria. Health Assessment Questionnaire
(HAQ) scores were also commonly reported, but in dif-
ferent ways across studies. In some cases, the publication
reported mean values at baseline and posttreatment,
while in other cases only the absolute or percentage
change from baseline were reported. ACR-based
response criteria were reported for all seven drugs, while
most of the other measures were available for three or
four drugs. Information on response rates across groups
based on the number of previous TNF-a inhibitor treat-
ments differed substantially by drug. The efficacy of eta-
nercept, for example, although available across a number
of response criteria, was explicitly reported only for
patients with one previous TNF-a inhibitor treatment
trial. In addition, some studies did not report the actual
drug used and presented results aggregated over the
three first-generation TNF-a inhibitors (adalimumab,
etanercept and infliximab). On the basis of the greatest
availability of data and relevance as markers of clinical
response, the following efficacy measures were selected:
ACR20, ACR50 and ACR70 rates; DAS28 low disease
activity rates (DAS28 ≤3.2) [54]; DAS28 remission rates
(DAS28 <2.6) [55]; and EULAR-based rates of moderate
and good responses [56].
Efficacy estimates based on number of previous TNF-a
inhibitors
Average response rates by number of TNF-a inhibitors
are shown in Figure 1 for ACR-, EULAR- and DAS28-
based response criteria. The bar graphs in Figure 1
show that for six of the seven indicators examined, the
likelihood of patient response to a subsequent biologic
treatment decreased slightly in patients with a greater
number of previous treatments with TNF-a inhibitors.
The main exception to the trend of decreasing likeli-
hood of response was the association between EULAR
moderate response rates and the number of previous
TNF-a inhibitors. Upon close examination, the study
characteristics do not appear to explain this difference
(see Table 2). From among the 10 studies used to derive
EULAR response rates, only three [33,36,45] reported
these rates on the basis of the number of previous TNF-
a inhibitors. For these three studies, within-study differ-
ences in good EULAR response rates consistently
declined with increasing number of previous TNF-a
Table 1 Biologic DMARDs for the treatment of RA
a
Generic drug name (brand
name, year of FDA
approval)
Structure and mechanism of action Mode and frequency of administration
TNF-a inhibitors
Infliximab (Remicade,
1999)
Chimeric monoclonal antibody that binds to TNF-a and blocks its
interaction with cell surface receptors
Intravenous infusion every 8 weeks
Etanercept (Enbrel,
1998)
Soluble human fusion recombinant protein that binds to TNF-a
and blocks its interaction with cell surface receptors
Subcutaneous injection weekly or twice weekly
Adalimumab (Humira,
2002)
Recombinant human monoclonal antibody that binds to TNF-a
and blocks its interaction with cell surface receptors
Subcutaneous injection every 2 weeks (or weekly
if methotrexate is not taken concurrently)
Golimumab (Simponi,
2009)
Human monoclonal antibody that binds to TNF-a and blocks its
interaction with cell surface receptors
Subcutaneous injection monthly
Certolizumab pegol
(Cimzia, 2009)
Recombinant, humanized, pegylated Fab’ of a monoclonal
antibody that binds to TNF-a and blocks its interaction with cell
surface receptors
Subcutaneous injection every 2 or 4 weeks, if
dosed at 200 mg or 400 mg, respectively.
Other biologic DMARDs
Abatacept (Orencia,
2005)
Soluble fusion protein that inhibits the costimulation of T-cells Intravenous infusion every 4 weeks
Anakinra (Kineret, 2001) Recombinant IL-1 receptor antagonist that inhibits the binding of
IL-1 to its receptor, thereby allowing regulation of IL-1 activity
Subcutaneous injection daily
Rituximab (Rituxan,
2006)
Chimeric monoclonal antibody that binds to the cell surface
protein CD20 and selectively depletes B-cells.
Intravenous infusion: two infusions separated by
2 weeks every 24 weeks or based on clinical
evaluation
Tocilizumab (Actemra,
2010)
Humanized IL-6 receptor that inhibits the binding of IL-6 to its
receptor, preventing IL-6 signal transduction
Intravenous infusion every 4 weeks
aDMARDs, disease-modifying antirheumatic drugs; Fab’, fragment antigen-binding region; RA, rheumatoid arthritis; FDA, Food and Drug Administration; TNF,
tumor necrosis factor; IL, interleukin.
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patients achieving a response to any biologic disease-modifying antirheumatic drug (DMARD) according to criteria commonly used in
rheumatoid arthritis (RA) patients, separated by number of biologic DMARDs to which the patients were exposed. With regard to the ACR
categories, ACR20 means a 20% improvement in tender or swollen joint counts as well as 20% improvement in at least three of the following
five criteria: patient assessment, physician assessment, erythrocyte sedimentation rate, pain scale and functional questionnaire. The ACR50 and
ACR70 categories adhere to the same criteria, but for 50% and 70% improvement, respectively. ACR, American College of Rheumatology; EULAR,
European League Against Rheumatism; DAS28, Disease Activity Score 28 joint count.
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study differences in moderate EULAR response rates by
number of previous TNF-a inhibitors did not show a
clear trend. For example, on the basis of the results of
the ReAct open-label trial [36], good EULAR response
rates were 35%, 25% and 11% for the first, second and
third TNF-a inhibitors administered, respectively, while
for moderate EULAR responses, these rates were 49%,
5 3 %a n d5 1 % ,r e s p e c t i v e l y .T h u s ,e v e nw i t h i nt h es a m e
study, the relationship between moderate EULAR
response rates and the number of previous TNF-a inhi-
bitors administered was different from the relationship
between good EULAR response rates and the number of
previous TNF-a inhibitors used.
Table 2 Information used to evaluate the proportion of patients achieving a response according to common criteria
used in RA studies
a
Measure Number of
biologics
used
Number
of
patients
Estimated
response
rate, %
Specific biologics
used to derive
response rate
Treatment
duration
range, months
Mean
age
range,
yr
Mean RA
duration
range, yr
Reference sources
ACR20 1 5,762 70.0 ADA 6 to 12 53 to 56 11 to 16 [30,36,51]
2 1,911 52.7 ADA, ETN, GLM, IFX,
TCZ, TNF2
3 to 12 45 to 57 9 to 17 [14,15,17,30,32,34,36,37,51-53]
2+ 772 53.3 ABA, RTX 6 to 12 52 to 53 12 [39,41,42]
3 339 40.6 ADA, GLM, TCZ, TNF3 3 to 6 51 to 58 11 to 15 [17,32,36,52]
4 66 31.9 GLM, TCZ 4 to 6 51 to 54 11 to 13 [32,52]
ACR50 1 5,736 41.1 ADA 3 to 12 54 to 56 11 to 16 [36,51]
2 1,699 30.1 ETN, TCZ, TNF2, ADA,
IFX
3 to 12 45 to 57 9 to 17 [14,15,17,32,34,36,37,47,51]
2+ 1,078 23.5 GLM, ABA, RTX 4 to 12 52 to 55 9 to 12 [39,41,42,52]
3 268 24.4 TCZ, TNF3, ADA 3 to 6 51 to 58 11 to 15 [17,32,36]
4 44 20.5 TCZ 6 51 to 54 11 to 13 [32]
ACR70 1 5,736 19.1 ADA 3 to 12 54 to 56 11 to 16 [36,51]
2 1,686 12.0 ADA, ETN, TCZ, TNF2 3 to 12 49 to 57 8 to 17 [5,17,32,34,36,37,47,51,53]
2+ 1,078 11.9 ABA, GLM, RTX 4 to 12 52 to 55 9 to 12 [39,41,42,52]
3 268 12.7 ADA, TCZ, TNF3 3 to 6 51 to 58 11 to 15 [17,32,36]
4 44 4.5 TCZ 6 51 to 54 11 to 13 [32]
DAS28
<2.6
1 5,711 21.0 ADA 3 54 11 [36]
2 1,604 14.9 ABA, ADA, TNF2 3 to 6 53 to 56 12 to 14 [17,29,36]
2+ 331 19.2 TCZ 6 51 to 54 11 to 13 [36]
3 496 10.2 ABA, ADA, TNF3 3 to 6 52 to 58 12 to 15 [17,29,36]
4 200 6.5 ABA 6 56 - [29]
DAS28
<3.2
2 1,219 22.7 ABA,TNF2 TNTNF2 3 to 6 55 to 56 8 to 14 [17,29,40]
2+ 331 33.7 TCZ 6 51 to 54 11 to 13 [32]
3 376 21.6 ABA TNF3 3 to 6 56 to 58 15 [17,29]
4 200 15.0 ABA 6 56 - [29]
EULAR
moderate
1 6,494 48.0 ADA, TNF 3 to 8 54 to 57 8 to 11 [33,36,45]
2 1,854 44.4 ADA, ETN, TNF2 3 to 12 53 to 61 8 to 13 [35-38,43,45]
2+ 324 49.7 TNF, RTX 6 to 9 52 12 [33,39]
3 120 51.0 ADA 3 52 12 [36]
EULAR
good
1 6,494 34.0 ADA, TNF 3 to 8 54 to 57 8 to 11 [33,36,45]
2 2,232 19.4 ADA, ETN, TNF2 3 to 12 53 to 61 8 to 14 [17,36-38,43-45,53]
2+ 324 15.3 TNF2+, RTX 6 to 9 52 12 [33,45]
3 156 10.5 ADA, TNF3 3 52 to 58 12 to 15 [17,36]
aRA, rheumatoid arthritis; ACR, American College of Rheumatology; DAS28, Disease Activity Score 28 joint count; EULAR, European League Against Rheumatism.
ABA, abatacept, ADA, adamlimumab, ANA, anakinra, ETN, etanercept, GLM, golimumab, IFX, infliximab, RTX, rituximab, TNFi, ith TNF-a inhibitor, TCZ, tocilizumab.
ACR20 means a 20% improvement in tender or swollen joint counts as well as 20% improvement in at least three of the following five criteria: patient
assessment, physician assessment, erythrocyte sedimentation rate, pain scale and functional questionnaire. The ACR50 and ACR70 categories adhere to the same
criteria, but for 50% and 70% improvement, respectively.
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the general trend was the fact that the proportion of
patients achieving low disease activity (DAS28 <3.2) and
remission (DAS28 <2.6) was higher among patients in
whom one or more TNF-a inhibitors had previously
failed (bars labeled “2+” in Figure 1) than for patients
with a single failed TNF-a treatment trial (bars labeled
“2” in Figure 1). The source of the 2+ group value was a
single RCT of tocilizumab [32] with a follow-up length
of 6 months, while the estimated response rates regard-
ing the second, third and fourth biologic treatments
were obtained from observational studies, several of
which had follow-up lengths of 3 months. In addition,
in one of these observational studies, DAS28 was evalu-
ated using C-reactive protein (CRP) level rather than
erythrocyte sedimentation rate (ESR) level. Although
CRP-based DAS28 scores are seen as a valid alternative
t ot h em o r ec o m m o n l yu s e dE S R - b a s e dD A S 2 8s c o r e s ,
there are reports that the former results in DAS28
values that are significantly lower [57,58], a finding that
agrees with the graphs shown in Figure 1.
Studies differed on a number of factors, such as type
of biologic, disease and treatment duration, which could
have a strong influence on these estimates (see Addi-
tional file 1, Table S1). To ascertain how the overall
estimates might have been affected by these factors,
stratified estimates were also evaluated.
Efficacy estimates stratified by type of biologic drug
(TNF-a inhibitors versus other biologics)
To examine whether the relationship between the num-
ber of previous TNF-a inhibitors and response rates
was different for TNF-a inhibitors when compared to
other types of biologic drugs (abatacept, rituximab or
tocilizumab), stratified response rates were evaluated for
these two main drug groups on the basis of ACR
response rates and DAS28 rates of low disease activity
and remission. It should be noted that the ACR
response rates for the “Other” biologics group shown in
Figure 2a are based on a single study of tocilizumab and
that the DAS-based rates are based on a single trial of
abatacept, limiting the value of the comparisons.
T h er e s u l t ss h o w ni nF i g u r e2 as u g g e s tt h a tt h ep r e -
viously observed trend of declining response rates with
increasing number of prior TNF-a inhibitors used per-
sists for both TNF-a inhibitors and alternative biologic
drugs. However, the ACR20 response rates were 54%,
42% and 14% for the second, third and fourth TNF-a
inhibitors used, respectively, whereas for tociluzimab,
the ACR20 rates were 49%, 50% and 54%, respectively.
For TNF-a inhibitors, DAS28-based response rates for
the third TNF-a inhibitor were approximately 10 per-
centage points lower than the rates for the second TNF-
a inhibitor, but this decline was only about three
percentage points in the alternative biologic drugs group
(abatacept). Overall, a decline in response for the second
versus the third biologic drug was generally reported for
both TNF-a inhibitors and biologic DMARDs with
other modes of action. However, the decline in response
rates tended to be more pronounced for TNF-a
inhibitors.
Efficacy estimates stratified by study design
Several authors have reported that efficacy estimates of
TNF-a inhibitors in patients naïve to biologic treatment
are consistently different in RCTs and observational stu-
dies [59,60]. To determine whether the relationship
between response rates and previous exposure to TNF-
a inhibitors was preserved within the type of study
design, estimates were also obtained after stratifying
across two main types of studies: RCTs and observa-
tional studies. As shown in Figure 2b, the trend was
essentially the same across the two types of study
design, although response rates based on RCTs tended
to be lower than those of observational studies. We
examined the role of several factors which could have
potentially influenced this result by comparing the char-
acteristics of the nine observational studies
[15,17,30,34,36,37,47,53] with those of the three RCTs
[14,32,52] used to derive the ACR-based response rates
shown in Figure 2b. These comparisons revealed that
t h et w os e t so fs t u d i e sw e r em o s t l ys i m i l a rw i t hr e s p e c t
to mean age (between 45 and 54 years of age for the
RCTs, and between 47 and 58 years of age for the
observational studies), disease duration (between 10 and
13 years for the RCTs, and between 9 and 17 years for
the observational studies) and time of efficacy assess-
ment. (Two (67%) of three RCTs and six (67%) of nine
observational studies reported efficacy at 3 and
4 months, while the remainder reported response rates
at 6 and 12 months.)
Further comparisons between RCTs and observational
studies indicated that whereas all nine observational stu-
dies examined the efficacy of TNF-a inhibitors (adali-
mumab, etanercept or infliximab), the three RCTs
assessed the efficacy of golimumab, infliximab and tocili-
zumab. The infliximab RCT [14] used a small sample of
27 patients and hence contributed relatively little to the
weighted ACR response rates. The two other RCTs had
similar, much larger sample sizes, but golimumab
response rates were substantially lower than those of
tocilizumab. For example, the golimumab ACR20 rates
for patients previously exposed to either one or two
TNF-a inhibitors were both 38%, while the comparable
tocilizumab ACR20 response rates were 49% and 50%.
Studies which did not report response rates by the
actual number of previously attempted TNF-a inhibitors
were excluded from the comparison shown in Figure 2b.
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Page 7 of 15Figure 2 Percentage of patients achieving a response by biologic type or study type and biologic number. (a) Bar graphs showing the
percentage of patients achieving the American College of Rheumatology ACR20, ACR50 or ACR 70 criteria (see description of these criteria in
Figure 1 legend), as well as remission (DAS28 <2.6) or low disease activity (DAS28 ≤3.2) according to the number of biologic disease-modifying
antirheumatic drugs (DMARDs) to which the patients were exposed and whether the drug switched to was a tumor necrosis factor (TNF)-a
inhibitor or a different type of biologic agent (Other). ACR20, ACR50 and ACR70 rates are based on 8 mg/kg tocilizumab, and DAS28 <2.6 and
DAS28 ≤3.2 are based on abatacept. (b) Bar graphs showing the percentage of patients achieving ACR-based improvement criteria according to
the number of biologic DMARDs to which the patients were exposed and type of study design. RCT, randomized controlled trial; Observational,
observational study.
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ACR20, ACR50 and ACR70 rates based on these trials
were 53%, 24% and 12%, respectively (see also Table 2
for further details), which are within the ranges formed
by the response rate estimates of the second and third
TNF-a inhibitors.
Comparisons of the two sets of studies with respect to
the reason for discontinuation were made difficult by
inconsistent reporting. In the set of RCTs, only the goli-
mumab trial [52] reported that lack of efficacy was a
reason for discontinuation of TNF-a inhibitor therapy
for 58% of study participants, while 53% of participants
also stated reasons unrelated to efficacy. For the inflixi-
mab [14] and tocilizumab trials [32], the reasons for dis-
continuation were either absent or not clearly stated. Six
of the nine observational studies included patients who
had discontinued therapy with a TNF-a inhibitor for
reasons other than inefficacy, with study percentages
ranging between 12% (5 of 41 patients) and 100% (37 of
37 patients). For observational study ACR20 response
rates, for example, we estimated that approximately
one-fourth of the total sample (396 of 1,512 patients)
had discontinued TNF-a inhibitor therapy for reasons
other than lack of efficacy. Overall, differences in report-
ing made it impossible to assess whether the reason for
discontinuation could have explained the lower response
rates observed among RCTs.
Efficacy estimates based on reason for discontinuation
The association between response rates and reasons for
discontinuation was evaluated by examining studies that
reported clinical response rates to a second TNF-a inhi-
bitor by reason for discontinuation of a first TNF-a
inhibitor. These studies were selected and weighted
rates were evaluated as described above and in Table 3.
A total of 12 publications [16,27-29,33-38,50,51,53] pro-
vided these rates for one or more of the following
groups according to reason for discontinuing a first
TNF-a inhibitor: (1) lack of efficacy (patients who never
achieved a response, also referred to as primary failures),
(2) loss of efficacy (patients who experienced a response
but lost this response over time, also referred to as sec-
ondary failures) and (3) intolerance and/or adverse
events (also referred to as safety failures).
Five publications which were initially identified for
potential inclusion in these analyses had to be excluded
because of problems in the way this information was
reported. Two studies [49,61] were excluded because
only change in continuous outcomes (HAQ and DAS28)
was reported. One study [58] which reported the effects
of adalimumab treatment among TNF-a inhibitor inade-
quate responders was excluded because the length of the
period leading up to assessment of response varied
between 1 and 19 months, making it difficult to inter-
pret the published rate. One study [52] was excluded
because it reported ACR response rates according to
whether the reason for discontinuation was related to
efficacy, which did not fit with the classification defined
above. A fifth study [47] was excluded because its elig-
ibility criteria limited the patient sample to those who
responded to treatment with infliximab and switched to
etanercept as a result of adverse events. We find that
this particular group of patients is likely not comparable
to those included in the remaining studies, since for
other studies patients were classified as safety failures
because this was the primary reason for discontinuation,
regardless of whether they had experienced an effective
response to the first TNF-a inhibitor.
Figure 3 presents the weighted ACR, DAS28 and
EULAR rates of response for a second TNF-a inhibitor
by reason for discontinuation of an initial TNF-a inhibi-
tor. It should be noted that DAS28-based remission
(DAS28 <2.6) rates were reported only for safety fail-
ures, making it impossible to compare the three groups
based on this response criterion. Response rates for pri-
mary versus secondary failures were not consistently
ordered across the six response criteria shown in
Figure 3. On the basis of ACR response rates, secondary
failures appear to have a greater likelihood of respond-
ing to a second TNF-a inhibitor. Contrary to this find-
ing, rates of EULAR moderate response suggested that a
greater proportion of primary failures would respond to
as e c o n dT N F - a inhibitor compared to secondary fail-
ures. The two remaining response criteria (EULAR good
and DAS28 ≤3.2) are generally too close to suggest a
clear difference between these two groups.
Two key differences may help explain the discrepan-
cies in these results. First, the study follow-up (or time
to assessment of response) tended to be somewhat
longer in the studies in which rates of DAS-based remis-
sion and rates of EULAR moderate response were
derived than in studies used to derive ACR and good
EULAR response rates. Second, these estimates were
often based on a few studies with total sample sizes that
ranged between 98 and 250 patients. In contrast, ACR
response rates and EULAR good response rates were
each estimated on the basis of four or more studies with
total sample sizes that ranged between 251 and 609
patients, making the ACR and EULAR good response
estimates somewhat more robust. Nearly 50% and 60%
of primary and secondary failures, respectively, were
estimated to achieve an ACR20 response. Overall, ACR
response rates were approximately 20% to 30% higher
for secondary failures when compared to those of pri-
mary failures.
In contrast to the results obtained for primary and
secondary failures, response rates to a second TNF-a
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Page 9 of 15inhibitor were consistently higher among patients who
switched for safety-related reasons. More than 60% of
safety failures were estimated to reach an ACR20
response, and about one-half (51%) were estimated to
experience a EULAR moderate response; approximately
one-third of these patients achieved an ACR50 response
and low disease activity (DAS28 ≤3.2).
Efficacy estimates stratified by length of follow-up
Since the ideal period for determining whether a
response to treatment has occurred remains controver-
sial [62] and varied considerably across the selected stu-
dies, we examined how efficacy varied by length of
follow-up or time of efficacy assessment. Differences in
ACR20 response rates for the second versus third biolo-
gic drug used were similar for treatment durations of 3
to 4 months and durations of 6 months or more (about
10% in both cases).
Discussion
In the current study, the association of response to sub-
sequent biologic treatment with number of previous
TNF-a inhibitor treatments was evaluated on the basis
of data reported in peer-reviewed publications. After
combining these data, the results indicated that an asso-
ciation does in fact appear to exist and that response is
likely to decline with increasing number of previous
TNF-a treatments. Our results also suggest that the pat-
tern of decreasing response for increasing number of
failed TNF-a inhibitors was maintained even when the
analyses were restricted to more homogeneous groups
of studies. Importantly, we found that the relationship
Table 3 Information used to evaluate the proportion of patients achieving a response to a second biologic DMARD
according to common criteria used in RA studies by reason for discontinuation of a first TNF-a inhibitor
a
Measure Reason for
discontinuation
Total number
of patients
Estimated
response rate,
%
Biologics used
to derive rate
Treatment
duration range,
months
Mean RA
duration range,
yr
Reference sources
ACR20 Intolerance 337 62.5 ADA and TNF2 3 12 [17,36,51,53]
Lack of efficacy 251 48.4 ADA and ETN 3 to 4 9 to 12 [34,36,37,53]
Loss of efficacy 609 58.0 ADA and ETN 3 to 6 9 to 12 [30,34,36,37,53]
ACR50 Intolerance 337 35.7 ADA and ETN 3 12 [17,36,51,53]
Lack of efficacy 251 23.6 ADA and ETN 3 to 4 9 to 12 [34,36,37,53]
Loss of efficacy 537 29.6 ADA and ETN 3 to 4 9 to 12 [34,36,37,53]
ACR70 Intolerance 337 13.4 ADA and TNF2 3 12 [17,36,51,53]
Lack of efficacy 251 9.0 ADA and ETN 3 to 4 9 to 12 [34,36,37,53]
Loss of efficacy 537 12.0 ADA and ETN 3 to 4 9 to 12 [34,36,37,53]
DAS28 <2.6 Intolerance 443 15.2 ABA and TNF2 3 to 6 NR [17,29]
DAS28 <3.2 Intolerance 211 30.4 TNF2 3 to 6 6 [17,35]
Lack of efficacy 98 13.0 TNF2 3 to 6 6 [35]
Loss of efficacy 150 12.0 TNF2 3 to 6 6 [35]
EULAR
moderate
Intolerance 250 38.8 TNF2 3 to 6 9 [38,45,50]
Lack of efficacy 98 37.0 TNF2 3 to 6 6 [35]
Loss of efficacy 150 18.0 TNF2 3 to 6 6 [35]
EULAR good Intolerance 718 21.3 ADA and TNF2 3 to 12 6 to 12 [17,35,36,38,45,50,53]
Lack of efficacy 320 15.2 ADA, ETN and
TNF2
3 to 6 6 to 12 [35-37]
Loss of efficacy 515 16.9 ADA, ETN and
TNF2
3 to 6 6 to 12 [35-37]
EULAR
moderate/
good
Intolerance 467 69.5 ADA and TNF2 3 to 6 6 to 12 [17,35,36,45,53]
Lack of efficacy 349 63.2 ADA, ETN and
TNF2
3 to 6 6 to 12 [34-37,53]
Loss of efficacy 687 60.7 ADA, ETN and
TNF2
3 to 6 6 to 12 [34-37,53]
aDMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; ACR, American College of Rheumatology; DAS28, Disease Activity Score 28 joint count;
EULAR, European League Against Rheumatism; ABA, abatacept, ADA, adalimumab, ETN, etanercept, TNFi, ith TNF-a inhibitor; ABA, abatacept; ADA, adamlimumab;
TNFi, i
th TNF-a inhibitor. ACR20 means a 20% improvement in tender or swollen joint counts as well as 20% improvement in at least three of the following five
criteria: patient assessment, physician assessment, erythrocyte sedimentation rate, pain scale and functional questionnaire. The ACR50 and ACR70 categories
adhere to the same criteria, but for 50% and 70% improvement, respectively.
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response measures, which further contributes to the
validity of the findings. Furthermore, the ACR response
rates derived in the current study for patients with no
prior exposure to biologic drugs are in line with those
reported in previous studies that examined 6-month
outcomes from RCTs using patients previously not
exposed to biologic DMARDs [10].
One limitation of the current study is that the degree
of heterogeneity across studies was not summarized
quantitatively. Nevertheless, it must be clear from our
exposition regarding the difficulties in combining results
across studies that a large degree of variation in study
design and patient characteristics was present. In addi-
tion, the results that were central to our research ques-
tion were frequently incidental to the primary objectives
of the studies that were reviewed, which meant that
information specific to groups of patients differing in
the number of prior TNF-a inhibitors used was often
lacking. Consequently, no formal statistical inference
was undertaken, which is another limitation of the
study.
Despite having found several results supporting a
trend of lower efficacy rates with increased number of
previous TNF-a inhibitors used, we believe that more
research into this topic is needed before a conclusion
Figure 3 Percentage of patients responding to a second TNF-a inhibitor by reason for discontinuation of first. Bar graph showing the
percentage of patients achieving a response to a second tumor necrosis factor (TNF)-a inhibitor according to criteria commonly used in
rheumatoid arthritis by reason of discontinuation of the initial TNF-a inhibitor. ACR, American College of Rheumatology (see Figure 1 legend for
description of ACR20, ACR50 and ACR 70 criteria); DAS28, Disease Activity Score 28 joint count; EULAR, European League Against Rheumatism.
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Page 11 of 15can be reached. In particular, the safety of biologic treat-
ment specifically in patients with an inadequate
response to TNF-a inhibitors must also be addressed
before the strategy of switching can be fully evaluated
vis-à-vis alternative therapies.
One potential key factor in predicting response after a
switch to an alternative biologic drug is the reason for
discontinuation of the prior drug. The current study
examined this aspect of RA treatment within the scope
of the available data on this topic, which did not enable
a comparison of patients who switched to a second bio-
logic DMARD that was not within the TNF-a inhibitor
class. Although several studies did report reasons for
discontinuation of prior TNF-a inhibitor treatment,
only a few reported response rates for groups of patients
who differed in the reason for discontinuation. Our
results indicate that patients who discontinue treatment
as a result of adverse events are more likely to achieve a
clinical response to a second TNF-a inhibitor than are
patients who discontinue the first TNF-a inhibitor for
efficacy-related reasons. Higher response rates [30] and
greater declines in DAS28 values [49] among safety fail-
ures have been reported in other studies. Nevertheless,
some caution should be taken when interpreting these
findings, since the assessment of these rates could be
sensitive to the length of follow-up in a particular study.
Two large studies based on registry cohorts [16,45]
reported that the reason for discontinuation of a first
TNF-a inhibitor was likely to explain the reason for dis-
continuation of a second TNF-a inhibitor, while the
findings from another large registry cohort could not
confirm this relationship [50]. Further, response rates in
a RCT of the newer biologic agent tocilizumab [52]
were nearly identical for patients who discontinued
treatment because of inefficacy or for unrelated reasons.
Overall, we observed consistently higher response rates
among safety failures than among primary and second-
ary efficacy failures. Data obtained over longer follow-up
periods, however, are needed to confirm or disprove the
findings of the current study.
The exact form of the relationship between response to
treatment and number of failed TNF-a inhibitors is likely
to play an increasingly important role in defining treat-
ment strategies for RA patients who have had an inade-
quate response to treatment with TNF-a inhibitors.
Given the high cost of biologic agents and evolving
knowledge of their safety profiles, there is a growing need
to compare and evaluate the relative benefit of strategies
involving alternative sequences of therapies. The recent
availability of a number of newer biologic drugs with dif-
ferent mechanisms of action makes this need even more
salient. Establishing patterns of response along the treat-
ment pathway is a key element of these evaluations, as is
the identification of subgroups of patients who may differ
in these response patterns. In addition to providing
insight into the existence of an association between treat-
ment response and increasing number of failed TNF-a
inhibitors, the current study has also offered an overview
of the multiple difficulties that are faced when synthesiz-
ing evidence pertaining to this question. Differences in
reporting, study design and the overall availability of data
have made this task a difficult one, which is apparent
from the results presented herein.
Given that a substantial proportion of patients will fail
an initial biologic treatment, establishing when and how
to initiate treatment with these agents is just as impor-
tant as establishing the relative value of long-term treat-
ment strategies. In many instances, these long-term
strategies involve a sequence of treatments, so the ques-
tion arises at each step which therapy to use as a repla-
cement when a particular therapy must be stopped
because of inefficacy or intolerance. Multiple studies
have addressed this question in a number of different
ways. To date, the large majority consist of observational
studies. Some of the results of earlier observational stu-
dies were based on small samples and relatively short
follow-up periods [29,44,46,51], but more recently the
accumulation of data from several registries of RA
patients [61] treated with biologic drugs has provided
larger sample sizes and longer duration of follow-up. In
addition, while the older biologic DMARDs were com-
pared primarily with nonbiologic DMARDs, RCTs of
newer biologic drugs have used samples of patients with
an inadequate response to one or more biologic
DMARDs, primarily TNF-a inhibitors [63]. Several
reviews [64-68] have attempted to summarize data from
these studies, but no clear guidance has emerged from
these publications. A recent meta-analysis [69] presented
a quantitative evaluation of the effectiveness of switch-
ing treatments, specifically between TNF-a inhibitors.
These results suggested that the probability of achieving
a clinical response declines after the first TNF-a inhibi-
tor, a trend that was observed in our study as well, even
when other biologic DMARDs were considered.
Although data were limited, we found that the magni-
tude of this decline may depend on the type of biologic
drug administered. For example, DAS28-based results
suggested that when the third biologic is a TNF-a inhi-
bitor, response rates may be lower than those of an
alternative biologic. Although readers are cautioned to
consider the limitations of the available data and the
preliminary nature of the findings, our study strengthens
and extends the findings presented in the meta-analysis
of Lloyd et al. [69].
Establishing the existence and magnitude of a relation-
ship between responses to biologic drug treatment and
the number of previously failed TNF-a inhibitors has a
number of important implications. From a clinical
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can help clinicians to decide on a treatment to use from
among an increasing number of alternative strategies.
From a research perspective, the current investigation
may help inform future studies that involve the treat-
ment of RA patients over the course of their lifetimes,
such as economic assessments of RA therapies based on
treatment sequence models. One of the key objectives of
this work was to provide a more quantitative analysis of
the data reported in studies of patients refractory to
TNF-a inhibitors, something that was lacking in the
current literature. In addition, the current study has
exposed some of the difficulties associated with combin-
ing results across studies with different designs, patient
populations and reported outcome measures. Exposing
these limitations may improve the design of future
research and foster greater harmonization of RA clinical
studies that aim to investigate the effects of sequential
biologic drug therapies in RA.
Conclusions
For patients with prior exposure to TNF-a inhibitors,
the likelihood of a response to subsequent treatment
with biologic agents declines with an increasing number
of previous TNF-a inhibitor treatments.
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